Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Non-Randomized, Multi-Center Phase-2 Study of Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma

NCT02858895 is registered in ClinicalTrials.gov with Medicenna Therapeutics, Inc. as lead sponsor.

NCT NCT02858895
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02858895 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Non-Randomized, Multi-Center Phase-2 Study of Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma
Lead sponsor
Medicenna Therapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
April 11, 2017
Completion date
October 31, 2019
Enrollment
47 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma, glioblastoma multiforme, grade iv astrocytoma, grade iv glioma